K Number
K190603
Date Cleared
2019-05-24

(77 days)

Product Code
Regulation Number
876.4620
Reference & Predicate Devices
Predicate For
AI/MLSaMDIVD (In Vitro Diagnostic)TherapeuticDiagnosticis PCCP AuthorizedThirdpartyExpeditedreview
Intended Use

The Ureteral Stent is intended to facilitate drainage from the kidney to the bladder via placement endoscopically, fluoroscopically or during an open surgical procedure by a trained physician.

Device Description

The Tria Firm Ureteral Stent consists of the following:

  • Tria™ Firm Ureteral Stent with retrieval line
  • Ureteral Stent Positioner
  • Pigtail Straightener
AI/ML Overview

The provided text is a 510(k) Summary for a medical device (Tria Firm Ureteral Stent) seeking substantial equivalence to a predicate device. This document describes performance testing of the device itself (a ureteral stent), not a diagnostic algorithm or AI system.

Therefore, the requested information (acceptance criteria for an AI system, study details like sample size for test/training sets, data provenance, number of experts, adjudication methods, MRMC studies, standalone performance, and ground truth establishment for AI) cannot be extracted from this document because it is not relevant to the type of device being described.

The document discusses performance testing related to the physical properties of the stent, such as:

  • Removal Force
  • Renal Coil Strength
  • Tapered Renal Tip
  • Retrieval Line to Stent Shaft Tensile Strength
  • Appearance and Cleanliness
  • Reversibility of Tip Configuration
  • Column Strength
  • Stent Softens at Body Temperature
  • Surface Roughness
  • Stent Identification Markers
  • Guidewire Compatibility
  • Biocompatibility

These tests ensure the physical device functions as intended and is biocompatible. They are not metrics for an AI system's diagnostic accuracy or performance.

{0}------------------------------------------------

Image /page/0/Picture/0 description: The image contains the logo of the U.S. Food and Drug Administration (FDA). On the left is the Department of Health and Human Services logo. To the right of that is the FDA logo, which is a blue square with the letters "FDA" in white. To the right of the blue square is the text "U.S. FOOD & DRUG ADMINISTRATION" in blue.

May 24, 2019

Boston Scientific Corporation Justin Kapitan Senior Regulatory Affairs Specialist Urology and Pelvic Health 100 Boston Scientific Way Marlborough, MA 01752

Re: K190603

Trade/Device Name: Tria Firm Ureteral Stent Regulation Number: 21 CFR 876.4620 Regulation Name: Ureteral Stent Regulatory Class: Class II Product Code: FAD Dated: April 22, 2019 Received: April 24, 2019

Dear Justin Kapitan:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal

{1}------------------------------------------------

statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR 803) for devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see https://www.fda.gov/CombinationProducts/GuidanceRegulatoryInformation/ucm597488.html; good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm.

For comprehensive regulatory information about mediation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/) and CDRH Learn (http://www.fda.gov/Training/CDRHLearn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (http://www.fda.gov/DICE) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).

Sincerely,

for

Glenn Bell, Ph.D. Assistant Director DHT3B: Division of Reproductive. Gynecology and Urology Devices OHT3: Office of Gastrorenal, ObGyn, General Hospital and Urology Devices Office of Product Evaluation and Quality Center for Devices and Radiological Health

Enclosure

{2}------------------------------------------------

Indications for Use

Form Approved: OMB No. 0910-0120 Expiration Date: 06/30/2020 See PRA Statement below.

510(k) Number (if known) K190603

Device Name Tria Firm Ureteral Stent

Indications for Use (Describe)

The Ureteral Stent is intended to facilitate drainage from the kidney to the bladder via placement endoscopically, fluoroscopically or during an open surgical procedure by a trained physician.

Type of Use (Select one or both, as applicable)
-------------------------------------------------
☑ Prescription Use (Part 21 CFR 801 Subpart D)
☐ Over-The-Counter Use (21 CFR 801 Subpart C)

CONTINUE ON A SEPARATE PAGE IF NEEDED.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff(@fda.hhs.gov

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."

{3}------------------------------------------------

510K SUMMARY

510(k) Summary for the Tria Firm Ureteral Stent

A. Sponsor

Boston Scientific Corporation Urology and Women's Health Division 100 Boston Scientific Way Marlborough, MA 01752

B. Contact

Justin Kapitan Sr. Regulatory Affairs Specialist 508-683-4518 justin.kapitan(@bsci.com

or

Virginia Garcia Regulatory Affairs Manager 508-683-4430 Virginia.garcia@bsci.com

C. Proposed Device

Trade name:Tria Firm Ureteral Sten
Common/usual name:Stent, Ureteral
Classification Number:21 CFR 876.4620
Classification Name:Ureteral Stent
Classification:Class II
Product Code:FAD
Product Code Name:Stent, Ureteral

D. Predicate Device

Trade name:Tria Firm Ureteral Stent
Common/usual name:Stent, Ureteral
Classification Number:21 CFR 876.4620
Classification Name:Ureteral Stent
Classification:Class II
Product Code:FAD
Product Code Name:Stent, Ureteral
Identification of Predicate Device:Tria Firm Ureteral Stent, K163399

{4}------------------------------------------------

510K SUMMARY

E. Model Name and Model Numbers

Model NumberModel NameSize(Fr x cm)
M0061902050Tria Firm Ureteral Stent4.8x10
M0061902060Tria Firm Ureteral Stent4.8x12
M0061902070Tria Firm Ureteral Stent4.8x14
M0061902080Tria Firm Ureteral Stent4.8x16
M0061902090Tria Firm Ureteral Stent4.8x18
M0061902100Tria Firm Ureteral Stent4.8x20
M0061902110Tria Firm Ureteral Stent4.8x22
M0061902120Tria Firm Ureteral Stent4.8x24
M0061902130Tria Firm Ureteral Stent4.8x26
M0061902140Tria Firm Ureteral Stent4.8x28
M0061902150Tria Firm Ureteral Stent4.8x30
M0061902200Tria Firm Ureteral Stent6x20
M0061902210Tria Firm Ureteral Stent6x22
M0061902220Tria Firm Ureteral Stent6x24
M0061902230Tria Firm Ureteral Stent6x26
M0061902240Tria Firm Ureteral Stent6x28
M0061902250Tria Firm Ureteral Stent6x30
M0061902300Tria Firm Ureteral Stent7x20
M0061902310Tria Firm Ureteral Stent7x22
M0061902320Tria Firm Ureteral Stent7x24
M0061902330Tria Firm Ureteral Stent7x26
M0061902340Tria Firm Ureteral Stent7x28
M0061902350Tria Firm Ureteral Stent7x30
M0061902400Tria Firm Ureteral Stent8x20
M0061902410Tria Firm Ureteral Stent8x22
M0061902420Tria Firm Ureteral Stent8x24
M0061902430Tria Firm Ureteral Stent8x26
M0061902440Tria Firm Ureteral Stent8x28
M0061902450Tria Firm Ureteral Stent8x30
Model NumberModel NameSize(Fr x cm)
M0061902550Tria Firm Ureteral Stent
M0061902560Tria Firm Ureteral Stent4.8x12
M0061902570Tria Firm Ureteral Stent4.8x14
M0061902580Tria Firm Ureteral Stent4.8x16
M0061902590Tria Firm Ureteral Stent4.8x18
M0061902600Tria Firm Ureteral Stent4.8x20
M0061902610Tria Firm Ureteral Stent4.8x22
M0061902620Tria Firm Ureteral Stent4.8x24
M0061902630Tria Firm Ureteral Stent4.8x26
M0061902640Tria Firm Ureteral Stent4.8x28
M0061902650Tria Firm Ureteral Stent4.8x30
M0061902700Tria Firm Ureteral Stent6x20
M0061902710Tria Firm Ureteral Stent6x22
M0061902720Tria Firm Ureteral Stent6x24
M0061902730Tria Firm Ureteral Stent6x26
M0061902740Tria Firm Ureteral Stent6x28
M0061902750Tria Firm Ureteral Stent6x30
M0061902800Tria Firm Ureteral Stent7x20
M0061902810Tria Firm Ureteral Stent7x22
M0061902820Tria Firm Ureteral Stent7x24
M0061902830Tria Firm Ureteral Stent7x26
M0061902840Tria Firm Ureteral Stent7x28
M0061902850Tria Firm Ureteral Stent7x30
M0061902900Tria Firm Ureteral Stent8x20
M0061902910Tria Firm Ureteral Stent8x22
M0061902920Tria Firm Ureteral Stent8x24
M0061902930Tria Firm Ureteral Stent8x26
M0061902940Tria Firm Ureteral Stent8x28
M0061902950Tria Firm Ureteral Stent8x30

{5}------------------------------------------------

510K SUMMARY

F. Device(s) Description

The Tria Firm Ureteral Stent consists of the following:

  • . Tria™ Firm Ureteral Stent with retrieval line
  • o Ureteral Stent Positioner

{6}------------------------------------------------

510K SUMMARY

  • Pigtail Straightener ●

F. Intended Use/Indications for Use

The Tria Ureteral Stent is intended to facilitate drainage from the kidney to the bladder via placement endoscopically, fluoroscopically or during an open surgical procedure by a trained physician.

G. Technological Characteristics Compared to Predicate

The principles of operation are identical between the predicate and subject devices: The Tria Firm Ureteral Stent provides a lumen that allows fluids to move from the kidney to the bladder.

The differences between the subject device and the predicate are minor. Differences include:

  • o Modification of processing of compounded resin used to manufacture the middle layer of the stent. Modification to address cosmetic observations on the final finished device.
  • Modification of the performance specification of surface roughness. Modified specification to compare to a predicate device.
  • Modification of the position of the laser etched text used for stent identification from the shaft of the stent to the bladder coil.
  • Addition of performance specification for accumulation of urine calcium and magnesium salts to align with claims in the Directions for Use cleared under K163399.

The technological characteristics remain equivalent to the predicate device because the modifications that are the subject of this submission are limited to improvements to the existing design.

H. Substantial Equivalence

The modified Tria Firm Ureteral Stent is substantially equivalent to the predicate Tria Firm Ureteral Stent (K163399). It has the same intended use for facilitating drainage from the kidney to the bladder and the same indications for use. The system design and principles of operation remain the same.

I. Biocompatibility

{7}------------------------------------------------

510K SUMMARY

Biocompatibility testing was performed to show that all patient contacting materials meet applicable biocompatibility standards per ISO 10993-1:2009 and the FDA guidance: Use of International Standard ISO 10993-1 "Biological evaluation of medical devices. Evaluation and testing within a risk management process."

The following testing was performed with passing results to support the biocompatibility of the device:

  • Cytotoxicity ●
  • Sensitization
  • Irritation ●
  • Accute Systemic Toxicity ●
  • Materials Mediated Pyrogenicity
  • Implantation
  • Chemical Characterization with Toxicological Risk Assessment (used to address ● systemic endpoints)

J. Performance Testing

The modifications to the subject Tria Firm Ureteral Stent have been tested in the same manner to ensure compliance to the initial specifications. Based on the change assessment including risk analysis, the following design verification tests were repeated. The test methods used were the same as those submitted for the predicate.

  • Removal Force
  • Renal Coil Strength ●
  • Tapered Renal Tip ●
  • Retrieval Line to Stent Shaft Tensile Strength ●
  • Appearance and Cleanliness ●
  • . Reversibility of Tip Configuration
  • Column Strength
  • . Stent Softens at Body Temperature
  • Surface Roughness
  • Stent Identification Markers
  • Guidewire Compatibility
  • Biocompatibility

The device continues to be sterilized by ethylene oxide (EO) to an SAL 106 level.

The conclusion of the assessments demonstrates that the modified device continues to function as intended in a manner equivalent to the predicate device. The modified device raises no new issues of safety or effectiveness compared to the predicate.

{8}------------------------------------------------

510K SUMMARY

K. Conclusion

Based on the test data, the same intended use, and same indications for use, the modified Tria Firm Ureteral Stent is substantially equivalent to its predicate, K163399.

§ 876.4620 Ureteral stent.

(a)
Identification. A ureteral stent is a tube-like implanted device that is inserted into the ureter to provide ureteral rigidity and allow the passage of urine. The device may have finger-like protrusions or hooked ends to keep the tube in place. It is used in the treatment of ureteral injuries and ureteral obstruction.(b)
Classification. Class II (performance standards).